+ Watch PPHM
on My Watchlist
A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.
Peregrine Pharmaceuticals, Inc. (PPHM), nothing personal, but a 5X rise in 5 weeks has to pop sometime. This is a frequent pattern on a biopharm whose cash burn is 2X its cash on hand. Expect some dilutive financing, wash, rinse, repeat, until hard catalysts are due. I've supported Peregrine in the past and I make no judgement on their long term chances, just on a $0.09 book value with over 100 million shares issued on an equity that was a hairs breath away from a delist or reverse split, but rose from the dredges on no pertinant news.Short term, retrace, equity financing issue, well below the $2.50 they spiked to.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions